FDA Approved: OXBRYTA — Supplemental Application (Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.)

View source ↗

Summary

FDA approved a supplemental application for OXBRYTA (voxelotor) from Global Blood Therapeutics, a subsidiary of Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

SUPPL AP for OXBRYTA (VOXELOTOR)